2 suspended. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Suspended 2 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis 10 mg/kg CM-101, Placebo - Systemic Sclerosis | Phase 2 | Suspended | ChemomAb Ltd. | 45 | 2026-09-01 | 2026-04-15 |
| Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis Patients will be randomized to receive EHP-101 or Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Suspended | Emerald Health Pharmaceuticals | 36 | 2020-06-11 | 2023-09-21 |
Connective Tissue Diseases (1) · Pathologic Processes (1) · Scleroderma, Diffuse (1) · Skin Diseases (1)
Skin and Connective Tissue Diseases (2) · Connective Tissue Diseases (1) · Pathological Conditions, Signs and Symptoms (1) · Skin Diseases (1)
streptococcal polysaccharide type III group B (1)
ChemomAb Ltd. (1) · Emerald Health Pharmaceuticals (1)
United States (2) · Australia (1) · New Zealand (1) · Puerto Rico (1)